Automate Your Wheel Strategy on IONS
With Tiblio's Option Bot, you can configure your own wheel strategy including IONS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IONS
- Rev/Share 5.9335
- Book/Share 3.9697
- PB 16.4799
- Debt/Equity 2.2478
- CurrentRatio 2.8723
- ROIC -0.0957
- MktCap 10427374201.0
- FreeCF/Share -1.8347
- PFCF -35.7145
- PE -38.8148
- Debt/Assets 0.4757
- DivYield 0
- ROE -0.4549
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | IONS | Goldman | Sell | Neutral | -- | $65 | Sept. 26, 2025 |
| Upgrade | IONS | BMO Capital Markets | Market Perform | Outperform | -- | $70 | Sept. 3, 2025 |
| Upgrade | IONS | Morgan Stanley | Equal Weight | Overweight | -- | $62 | July 31, 2025 |
| Upgrade | IONS | Barclays | Equal Weight | Overweight | -- | $57 | July 1, 2025 |
| Initiation | IONS | H.C. Wainwright | -- | Buy | -- | $45 | April 7, 2025 |
| Initiation | IONS | Redburn Atlantic | -- | Neutral | -- | $39 | March 31, 2025 |
News
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Read More
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Published: September 22, 2025 by: Benzinga
Sentiment: Positive
Ionis Pharmaceuticals, Inc. IONS released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.
Read More
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Read More
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Okay. Thank you, everyone, for being here.
Read More
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Read More
Is The 35% Rally In IONS Stock Just The Beginning?
Published: September 03, 2025 by: Forbes
Sentiment: Positive
Ionis Pharmaceuticals' stock jumped 35% on September 2, 2025, after positive late-stage clinical trial results for olezarsen, a therapy for severe hypertriglyceridemia (sHTG). Investor enthusiasm is anchored in olezarsen's estimated peak sales potential of $2.5 billion—a figure that towers over Ionis' current twelve-month revenue of $944 million.
Read More
Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Gerberry - BofA …
Read More
Ionis shares jump after drug lowers blood fat levels in advanced trials
Published: September 02, 2025 by: Reuters
Sentiment: Positive
Ionis Pharmaceuticals' shares surged on Tuesday before the bell after the drugmaker said its experimental treatment significantly reduced levels of blood fats called triglycerides and reduced pancreatitis risk in two large late-stage studies.
Read More
Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive
Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary angioedema is significant, with potential for near-blockbuster status if it captures a 20% share of a ~$5bn market. Upcoming catalysts — including olezarsen's sHTG data and eplontersen's ATTR-CM results — could drive Ionis toward profitability and a higher valuation.
Read More
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Published: August 21, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute a.
Read More
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Read More
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.
Read More
Ionis reports second quarter 2025 financial results and highlights progress on key programs
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025. “During the second quarter, we continued to build momentum across our business,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our strong performance included excellent commercial execution, resulting in a substantial increase in TRYNGOLZA revenues, our first independently launched med.
Read More
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were published in The Journal of Allergy and Clinical Immunology (JACI) In Practice. Results indicate that patients who switched to donidalorsen from prior prophylactic treatments showed a 62% further reduction in mean monthly HAE attack rate from baseline, and 84% of p.
Read More
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Ionis Pharmaceuticals, Inc. (IONS) could be a good stock pick from a technical perspective. IONS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Read More
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
Read More
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to
Read More
Ionis to host 2025 virtual Annual Meeting of Stockholders
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we.
Read More
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Read More
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David …
Read More
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.
Read More
Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG - a "blockbuster" indication. Management believes >$3bn revenues and >$2bn royalties + milestones may be achieveable long-term, with multiple new product launches for wholly-owned and partnered assets.
Read More
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Read More
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over 40 RNA-targeted therapeutics, making it a compelling watch-list candidate.
Read More
About Ionis Pharmaceuticals, Inc. (IONS)
- IPO Date 1991-05-17
- Website https://www.ionispharma.com
- Industry Biotechnology
- CEO Brett P. Monia
- Employees 1069